Alan Xu
Directeur des opérations chez Ablaze Pharmaceuticals
Profil
Alan Xu is currently the Chief Operating Officer at Ablaze Pharmaceuticals.
He completed his undergraduate degree from Fudan University in 1995 and later earned an MBA from the same university in 2007.
Postes actifs de Alan Xu
Sociétés | Poste | Début |
---|---|---|
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Directeur des opérations | - |
Formation de Alan Xu
Fudan University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 1 |
---|---|
Ablaze Pharmaceuticals
Ablaze Pharmaceuticals Pharmaceuticals: MajorHealth Technology Ablaze Pharmaceuticals is a Chinese clinical-stage pharmaceutical company founded in 2021 with a mission to bring advanced targeted radiopharmaceutical therapies to benefit cancer patients. Ablaze Pharma has secured a partnership with Rayzebio, Inc., an innovative radiopharmaceutical company based in CA, to gain exclusive development and commercial rights to a series of Rayzebio's products in the greater region. The company is based in Jing'an District, China. The company leverages its team's extensive business experience and network in cross-border product development and deal making to become the leader and partner of choice in the emerging TRT market. Alex Qiao has been the CEO of the company since 2021. | Health Technology |